We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
167 result(s) found, displaying 61 to 70
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XULTOPHY insulin degludec 100 units/mL liraglutide 3.6 mg/mL solution for injection pre-filled pen 3 mL.
-
Designation or determinationPriority review
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Prescription medicine registrationActive ingredients: Semaglutide.
-
Prescription medicine decision summaryTGA decision: Sogroya (somapacitan) is approved to treat adults with growth hormone deficiency (AGHD).
-
Prescription medicine decision summaryTGA decision: Rybelsus (semaglutide) is approved to treat type 2 diabetes mellitus
-
Prescription medicine registrationActive ingredients: somapacitan.
-
Prescription medicine registrationActive ingredients: semaglutide.